<DOC>
	<DOCNO>NCT01509196</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics safety oral administration HIP0901 capsule Lipidilsupra tablet .</brief_summary>
	<brief_title>A Bioequivalence Study Comparing HIP0901 Capsule With Lipidilsupra Tablet</brief_title>
	<detailed_description />
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Healthy male volunteer , age 20 45 Informed investigational nature study voluntarily agree participate study Weight＞50kg , BMI ＞18kg/m2 ＜27kg/m2 subject Acute disease within 28 day prior start study drug administration Use prescription medication within 14 day prior Day 1 Use medication within 7 day prior Day 1 Has severe medical history hypersensitivity fibric acid derivative Participation another clinical study within 30 day prior start study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Fenofibric acid</keyword>
	<keyword>HIP0901</keyword>
	<keyword>Lipidilsupra</keyword>
</DOC>